As a physicist, Dr. Mark Rivard is fascinated by brachytherapy’s ability to provide “conformal, localized” radiotherapy compared to external-beam radiation therapy for treatment of multiple cancer types. He was kind enough to share his thoughts with us in a video...
RICHLAND, WASHINGTON – December 3, 2018 – IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Jonathan Hunt has been named Chief Financial Officer...
Building community around the power of Cesium The radiation oncologist community is one of the cornerstones on which we are building the future of brachytherapy at Isoray. As such, in person engagements at the ASTRO Annual Meeting are some of our most important...
The International Journal of Radiation Oncology recently published a study titled Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer. This study aimed to evaluate the effects on survival rate in patients...
Year Over Year First Quarter Revenues Increased 29% Double Digit Revenue Increases Year Over Year for Sixth Consecutive Quarter RICHLAND, WASHINGTON – November 8, 2018 — IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in...
Dr. R. Alex Hsi is a Radiation Oncologist at the Peninsula Cancer Center in Poulsbo, Washington. As a practitioner of various prostate radiation treatments like external beam radiation and stereotactic body radiation therapy in addition to brachytherapy, he offers an...
Conference Call is November 8 at 4:30 p.m. ET/1:30 p.m. P RICHLAND, WASHINGTON – October 24, 2018 – IsoRay, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today...
Barbara Touchstone first survived cervical cancer following a radical hysterectomy, radiation and chemotherapy. In spite of the debilitating rigor of her initial course of treatment, the cancer returned in 2015. As a 35-year-old nurse and mother, she had reached the...
Radiation Oncologist Dr. John Sylvester, MD shared a few minutes with us at ABS 2018 discussing recent advancements in prostate brachytherapy and their implications for prostate cancer patients. “Prostate brachytherapy has the highest cure rate for prostate cancer...
Dr. John Sylvester is considered a pioneer in prostate cancer brachytherapy, having performed over 6,000 prostate brachytherapy procedures to date. It’s no surprise that he is well-versed in its history. “Brachytherapy was [first] used for prostate cancer in 1911 and...
